Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Safety of Rasagiline in Elderly Patients with Parkinson Disease
Neurol 66:1427-1429, Goetz,C.G.,et al, 2006
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005
Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005
Monoamine Oxide Type B Inhibitors in Early Parkinson's Disease:Meta-Analysis of 17 Randomised Trials Involving 3525 Patients
BMJ 329:593-596, Ives,N.J.,et al, 2004
Mortality in People Taking Selegiline:Observational Study
BMJ 317:252-254, Thorogood,M.,et al, 1998
Selegiline and Mortality in Parkinson's Disease
Ann Neurol 40:841-845, Olanow,C.W.,et al, 1996
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993
Selegiline as Initial Treatment of De Novo Parkinsonian Patients
Neurol 42:339-343, Myllyla,V.V.,et al, 1992
The Antiparkinson Efficacy of Deprenyl Derives from Transient Improvement that is Likely to be Symptomatic
Ann Neurol 32:795-798, Schulzer,M.,et al, 1992
Pergolide and Selegiline for Parkinson's Disease
The Medical Letter, 31:81-841989., , 1989
The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Science 245:519-522, Tetrud,J.W.&Langston,W., 1989
Current Theories on the Cause of Parkinson's Disease
JNNP Suppl (June) 52:13-17989., Langston,J.W., 1989
Selegiline Use to Prevent Progression of Parkinson's Disease
Arch Neurol 46:1275-1279, Elizan,T.S.,et al, 1989
DATATOP:A Multicenter Controlled Clinical Trial in Early Parkinson's Disease
Parkinson Study Group, Arch Neurol 46:1052-10601989., , 1989
MPTP:A Neurotoxin Relevant to the Pathophysiology of Parkinson's Disease, The 1985 George Cotzias Lecture
Neurol 36:250-258, Snyder,S.H.&D'Amato,R.J., 1986
Deprenyl In Parkinson's Disease
Lancet 2:695-696, , 1982
Deprenyl in Parkinson Disease
Neurol 31:19-23, Eisler,T.,et al, 1981
Considerations in the Management of Parkinsonism
Neurol 28:5, Fahn,S.,et al, 1978
Drug Therapy of Parkinsonism
NEJM 295:814, Bianchine,J.R., 1976
Neurotoxicity of Commonly Used Antineoplastic Agents
NEJM 291:75, 1271974., Weiss,H.,et al, 1974
Drug Therapy of Parkinsonism
NEJM 287:20, Yahr,M.,et al, 1972